Glass Label/Claim Audit

Anxiolysis

Durable audit route for one claim-like target. This page shows source-use records, assessment rationale, active challenges, revisions, and graph edges tied to the same target identity.

evidence low
Assessment Rationale

anxiolysis is included with provisional confidence because the record has direct section evidence but still needs endpoint-specific interpretation before it should be read as a strong clinical claim.

The assessment is anchored to the cited effect record rather than inferred from the compound name alone.

Evidence Reviewed

Sources considered for this assessment[1]

Claim Scope
Endpoint
Anxiolysis
Context
Effect
Does not mean
  • - Not proof that every user will experience this effect
  • - Not a complete effect-size claim
  • - Not individualized medical guidance
Basis For Judgment
01Record supportMedium

The row has an explicit structured record and citation mapping.

02Endpoint directnessLow

The current seed evidence does not yet carry the same detailed endpoint interpretation as Taurine.

03CMS readinessMedium

The audit path is present; additional source interpretation can be added without changing the schema.

Raises confidence
  • - structured record exists
  • - citation support is mapped to this row
Limits confidence
  • - interpretation remains provisional
  • - effect size and population scope need fuller review
Disputable assumptions
  • - endpoint inference
  • - population generalization
  • - whether the row should be strengthened or narrowed
Source Use Records

Local evidence attached to this claim

MixedDirect Endpoint EvidenceDirect Nonhuman Endpoint5/5 quality fields

Apigenin, GABAergic signaling, and sleep-related behavior

Associated with calming and anxiolytic-like activity in mechanistic and preclinical models.

This source is used to support the Anxiolysis effect row in this compound monograph.

Endpoint
Anxiolysis
Population
Healthy adults or mixed adult populations
Dose / Exposure
25-50 mg/day or dietary intake levels
Duration
Single dose to 12 weeks
Directness
Direct Nonhuman Endpoint